What's Next For Atezolizumab
Executive Summary
Roche has embarked on an extensive program of Phase II and III studies for its PD-L1 inhibitor. The initial BLA filing is expected to be for non-small cell lung cancer in early 2016, with indications in bladder, kidney and triple-negative breast cancer to follow.